Importantly, the fact that S100B, like DNAJB6 [65,66] and the Brichos domain [67,68,69], are able to inhibit Aβ42 secondary nucleation, which is the main route to generate toxic oligomers, makes this type of proteins attractive inspirations for translational AD therapies [70,71,72]. Here, S100B is linked to Alzheimer disease.